Bicitropeptide, antacid and placebo in gastric and duodenal ulceration. A two-centre, double-blind, comparative endoscopic study.

Abstract

A bismuth-peptide complex (BCP Compound), an antacid (Maalox) and corresponding placebos were studied in a 6-week comparative double-blind trial of treatment in 106 randomized ambulant patients with endoscopically proven duodenal and gastric ulcers. Patients were examined after 1, 3 and 6 weeks' treatment and results assessed separately for duodenal and gastric ulcers on endoscopic evidence at weeks 3 and 6 respectively. Bicitropeptide was significantly better than antacid and placebo at 3 and 6 weeks for treatment of both duodenal and gastric ulcers. In the bicitropeptide group 100% of the patients in the duodenal ulcer group and 95,2% in the gastric ulcer group responded to treatment (improved or healed). No haematological or biochemical changes were noted and no adverse effects were recorded.

• Authors: R C Mekel, W J Serfontein, S Bank, G O Barbezat, B H Novis
• Journal: South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde (S Afr Med J) Vol. 55 Issue 2 Pg. 43-6 (Jan 13 1979) ISSN: 0256-9574 [Print] South Africa
• PMID: 371034 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Antacids
• Placebos
• Proteins
• Bismuth

Topics

• Adult
• Antacids (therapeutic use)
• Bismuth (therapeutic use)
• Clinical Trials as Topic
• Double-Blind Method
• Drug Evaluation
• Duodenal Ulcer (drug therapy)
• Female
• Humans
• Male
• Peptic Ulcer (drug therapy)
• Placebos
• Proteins (therapeutic use)